Претраживање
Приказ резултата 11-20 од 42
JAK2-mutant hematopoietic cells display metabolic alterations that can be targeted to treat myeloproliferative neoplasms
(Amer Soc Hematology, Washington, 2019)
Increased energy requirement and metabolic reprogramming are hallmarks of cancer cells. We show that metabolic alterations in hematopoietic cells are fundamental to the pathogenesis of mutant JAK2-driven myeloproliferative ...
Monitoring of leukocyte-platelet aggregates and selectin levels in patients with philadelphia-negative myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2017)
Predictors of survival in patients with essential thrombocythemia
(Ferrata Storti Foundation, Pavia, 2015)
Transcriptional profiling of human erythroid progenitors from g-csf mobilized and nonmobilized peripheral blood
(Ferrata Storti Foundation, Pavia, 2013)
Human mesenchymal stem cells creating an immunosuppressive environment and promote breast cancer in mice
(Nature Publishing Group, London, 2013)
Human mesenchymal stem cells (hMSC) can home to tumor sites and promote tumor growth. The effects of hMSC on tumor growth are controversial and involvement of hMSC in tumor immunology has not been adequately addressed. ...
Proinflammatory cytokine il-6 stimulation of angiogenic factors and DNA replication is blocked by jak-stat pathway inhibition in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2017)
A prognostic model to predict thrombosis in essential thrombocythemia
(Ferrata Storti Foundation, Pavia, 2014)
Oxidative stress in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2014)
Proangiogenetic molecules vegf, hif-1alpha and enos in myeloproliferative neoplasms
(Ferrata Storti Foundation, Pavia, 2013)
Addition of the degree of bone marrow fibrosis to IPSS in new scoring system improve prediction of survival in primary myelofibrosis
(Ferrata Storti Foundation, Pavia, 2013)